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Among all coronary lesions, the decision-making process for the treatment of unprotected left main (ULM) stem
lesions is still challenging. Indeed, the optimal therapeutic strategy for patients with ULM disease remains
controversial: coronary artery bypass grafting was established as the gold standard, but it is without doubt that
percutaneous coronary intervention (PCI) performed by experienced operators achieves good results at long term
follow up, especially in cases where the ostium and/or shaft of ULM are treated. Thanks to the widespread use of
invasive assessment of atherothrombotic ULM stenosis, improved selection of PCI cases and techniques of stenting,
better outcomes are now possible. This review seeks to define the place of PCI in ULM disease by describing the
different modalities of ULM stenosis assessment.
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MLD = minimal lumen diameter
OCT = optical coherence tomography
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QCA = quantitative coronary analysis
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Isolated unprotected left main (ULM) involve-ment is observed in 7% of coronary artery dis-
eases (CAD), and in 13%, 17% and 27% of cases it
is associated with single, double and triple vessel
disease respectively [1,2]. The optimal therapeutic
strategy for patients with ULM disease remains
controversial. Although coronary artery bypass
grafting (CABG) was established as the gold stan-
dard for treatment of patients with ULM disease
[3], in the last decade, percutaneous coronary
intervention (PCI) for this lesion subset is increas-
ing, especially where the atherothrombotic dis-
ease is located at ostium and/or shaft of left
main stem [4–11]. Indeed, for this type of lesion,
PCI is associated with good long-term outcomes
and may represent a valid alternative therapy to
CABG [12,13]. Current European guidelines
assign a Class IIb, Level of Evidence: B indication
for PCI in patients with distal left main bifurca-
tion, either isolated or with concomitant single
vessel disease [14].
The rationale for use of intracoronary physiol-
ogy assessment and imaging arises from the limi-
tations of coronary angiography in determining
the severity of coronary stenoses. The visual
assessment of percent diameter reduction has sig-
nificant inter-observer variability even among
experienced interventional cardiologists [15].
In addition, the widespread use of invasive
imaging modalities has determined a better
understanding of the process, which can be related
to restenosis and stent thrombosis, underlining the
importance of an invasive assessment of ULM ath-
erosclerotic plaque in order to choose the best
strategy to adopt. This review tries to define the
place of PCI in ULM disease and describes the dif-
ferent modalities of ULM stenosis assessment.CABG or PCI: a delicate choice
In an older study, Cohen and Gorlin [16]
revealed that CABG improves 10-year survival
when compared with medical therapy in patients
with significant ULM stenoses. This finding was
subsequently confirmed by several randomized
trials [3]. Therefore, in clinical practice today, the
gold standard of treatment for ULM stenosis is
represented by CABG. Since the beginning of
the angioplasty era, ULM PCI has represented
an attractive target for interventionalists in rela-
tion to its relatively large diameter and proximal
location (which do not determine technical prob-
lems related to deliverability of device). However,
three anatomical features have a capital impactand need to be considered. First, isolated ULM
stenoses are only observed in 7% of patients,
whereas over 70–80% of patients also have multi-
vessel CAD [2,3,16]. In such cases, CABG could
be preferred in order to achieve a complete revas-
cularization. Second, most ULM stenoses (40–94%)
concern the distal segment of ULM [2,3,16]. Such
bifurcated or trifurcated lesions have high proce-
dural risks and present high rates of restenosis
[3], and a possible acute occlusion (stent thrombo-
sis) may have catastrophic consequences. Finally,
the presence of calcification is common [17], lead-
ing to difficulties in stent expansion.
On the other hand, CABG may be associated
with high risk of mortality in patients with
co-morbidities in comparison with PCI [18]. Thus,
for the correct choice of a revascularization
strategy in case of ULM disease, the stratification
of procedural risk is as imperative as a careful
evaluation of the long-term benefits of both PCI
and CABG. Several methods of stratifying risk
in patients undergoing ULM revascularization
are available. Risk scores can be divided into
those using clinical-based parameters, those
using angiographic variables, and those using a
combination of both.
The European System for Cardiac Operative
Risk Evaluation (EuroSCORE) [19] is an additive
clinical score including 17 objective clinical vari-
ables. The utility of using the EuroSCORE in
patients undergoing PCI has been evaluated in
the SYNTAX study [20], and several additional
non-randomized studies [21–23]. Additive Euro-
SCORE was shown to be an independent predictor
of MACCE not only in patients with ULM disease
undergoing PCI [22–24], but also in those undergo-
ing CABG [22–23]. Rodés-Cabau et al. [24] found
that in octogenarians EuroSCOREP 9 identified
as the best predictor of major adverse cardiac
and cerebral events (MACCE) after PCI and CABG
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monly accepted as a high-risk surgical group [19],
was also shown to be an independent predictor
of death and myocardial infarction.
The Society of Thoracic Surgeons (STS) scale
aims to accurately estimate peri-operative risk
complications such as mortality, stroke, kidney
failure, prolonged mechanical ventilation or infec-
tion [25]. Although it was only verified among sur-
gical patients, it could be a useful diagnostic tool
to choose the appropriate method of revasculari-
zation, if verified in the PCI LMD group [25,26].
Other clinical scores such as the ACEF score [27]
and the Mayo Clinic risk score [28] have also been
evaluated. No clinical score takes account of the
presence and severity of LM disease except for
the STS-score [25]. Table 1 provides an overview
of the variables evaluated in the score systems.
Various scores based on angiographic data have
been proposed. The SYNTAX score was first pro-
spectively used in the SYNTAX trial and has since
been used in different clinical trials, in both acute
and elective patients [29,30]. The SYNTAX score
has a capital role to play not only in stratifying
clinical outcomes, but also in assisting important
revascularization decisions in patients undergoing
revascularization of ULM disease. In the ULM
subgroup of the SYNTAX study, the SYNTAX
score was an independent predictor of MACCE
for patients undergoing PCI, but not for those
undergoing CABG. At two-year follow up, in high
SYNTAX score tertile (P32) patients, the MACCE
rate was higher in the PCI group (29.7% vs. 17.8%,
p = 0.02) [20]. This may be because the bypass
anastomosis occurs distal to the complex disease.
However, at four-year follow up, Farooq et al.
[31] found a trend towards increased mortality in
the high CABG SYNTAX score group (9.1% vs.
1.8% for low CABG SYNTAX score group;Table 1. Summaries of variables evaluated in different clinical scor
Euroscore S
Age X X
Sex X X
Ethny X
Body mass index X
COBP X X
Peripheral arteriopathy X X
Neurological dysfunction X X
Renal function X X
Previous cardiac surgery X X
Clinical presentation X X
Left ventricular ejection fraction X X
Critical perioperative state X X
Operation related factor X X
Left main disease Xp = 0.084); and an increase in the composite MAC-
CE (7.0% vs. 16.4%; p = 0.126).
The European Society of Cardiology and the
European Association for Cardio-Thoracic Sur-
gery Guidelines on myocardial revascularization
address the indications for CABG compared with
left main PCI in stable patients with lesions suit-
able for both procedures and low predicted surgi-
cal mortality [14]. These guidelines provide a
Class IIa (Level of Evidence: B) recommendation
for PCI of left main ostial or shaft disease when
it exists in isolation or in combination with one-
vessel disease; a Class IIb (Level of Evidence: B)
recommendation for left main distal bifurcation
disease when it exists in isolation or in combina-
tion with one-vessel disease; a Class IIb recom-
mendation for any left main disease with
concomitant two- or three-vessel disease and a
SYNTAX score 632; and a Class III recommenda-
tion for left main disease with concomitant two- or
three-vessel disease and a SYNTAX score >32.
CABG is the favored approach for all of these sce-
narios (Class I, Level of Evidence: A) [14]. The
importance of considering both clinical and angio-
graphic variables in the assessment of overall risk
has led to the use of combined risk scores such as
SYNTAX score II.
Indeed, SYNTAX score II provides an impartial,
evidence-based assessment of the decision-
making process for clinicians weighing anatomical
and clinical factors to establish the optimum
revascularization technique for individual
patients with complex coronary artery disease.
Such an instrument might help to more clearly
and objectively define the often uncertain line that
separates patients for whom PCI or CABG should
be considered, as reported in appropriate-use cri-
teria for coronary revascularization. This score
should be used by heart teams consisting of ae systems.
TS-score ACEF score Mayo clinic score
X X
X
X X
X
X X
X
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interventionalist to comply with international
revascularization guidelines (Class 1 indication)
[14], and to remove any possibility of individual
bias in interpretation in order to select the safest
and more efficient revascularization strategy.
In a large retrospective series of consecutive
patients who underwent ULM PCI, Genereux
et al. [32] confirmed the prognostic capability of
the SYNTAX score II for mortality among patients
with complex coronary artery disease. CABG pref-
erence based on SYNTAX score II was an inde-
pendent predictor of mortality (HR = 4.13; 95%
CI: 1.59–10.7; p = 0.004) after ULM PCI.
Finally, the ULM revascularization strategy
should take into account patient preference and
operator experience to achieve the optimal result.Invasive assessment of ULM disease
Coronary angiography limits
Coronary angiography is still the standard tool
for the assessment of coronary artery stenoses.
While angiographic assessment of severe lesions
is usually straightforward, the correct interpreta-
tion of intermediate lesions may be more challeng-
ing with a substantial inter-observer difference
[33,34]. ULM anatomy, associated with vessel
foreshortening and overlap, makes angiographic
assessment difficult. Indeed, ostial left main
lesions may appear more significant than they
truly are, due to catheter-induced artifacts,
whereas the severity of distal bifurcation lesions
may be notoriously difficult to delineate accu-
rately. Moreover, with only angiograms it is hard
to delineate the correct understanding of plaque
distribution at the bifurcation carina in case of dis-
tal ULM disease (Table 2).
It has been previously shown that prognosis
in patients with ULM lesions that are non-
functionally significant is favorable [35]. Moreover,
CABG performed in non-hemodynamically signif-
icant lesions may lead to its early failure [36]. ForTable 2. Comparison of different invasive assessment modalities.
Angiograms
Quantitative analysis ++
Functional assessment –
Plaque composition identification +
Vessel wall morphology identification –
Identification of thronbus burden +/–
Evaluation of stenting result +/–
Evaluation of ostial ULM disease +/–
IVUS intra vascular ultrasound; OCT optical coherence tomography; FFR fraall these reasons, a suspicious or borderline ULM
lesion warrants further evaluation before either
suggesting the need for revascularization or dis-
missing the need altogether [35–38].
Intravascular ultrasound
Several studies have shown that intravascular
ultrasound (IVUS) is able to demonstrate signifi-
cant left main disease in a very high percentage
of angiographically normal patients [39–41].
Hermiller et al. [39] reported no correlation
between IVUS and quantitative coronary angiog-
raphy (QCA) lumen dimensions in patients with
angiographically detectable left main disease.
Many authors found that QCA underestimated
the size of coronary vessels, and IVUS has been
shown to detect LM disease that is angiographi-
cally silent [42,43].
Abizaid et al. [44] assessed the severity of left
main stenosis in 122 patients by angiography
and IVUS. Those patients did not have subse-
quent interventions and were followed up for
one year to correlate angiographic and IVUS find-
ings and identify predictors of subsequent coro-
nary events. The event rate at one year was 14%.
IVUS measurement of minimal lumen diameter
(MLD) was the most important quantitative pre-
dictor of cardiac events. For any given MLD, the
event rate was exaggerated in the presence of dia-
betes mellitus or an untreated lesion in a major
vessel [44].
On the other hand, Fassa et al. [45] conducted
IVUS studies on 214 patients with angiographically
indeterminate ULM lesions. The lower range of
normal ULM minimal lumen area (MLA) was
7.5 mm2. Of the patients with angiographically
indeterminate ULM, 38.8% had an MLA
<7.5 mm2, and 61.2% had MLA P7.5 mm2. ULM
revascularization was performed in 85.5% of
patients with an MLA <7.5 mm2 and deferred
in 86.9% of patients with an MLA P7.5 mm2.
Long-term follow up showed no significant differ-
ence in major adverse cardiac events between
patients with an MLA <7.5 mm2 who underwentIVUS Virtual histology OCT FFR
+++ + +
– – – +++
+++ +++ ++ –
+++ +++ + –
+ + +++ –
++ + +++ –
+ + – –
ctional flow reserve; ULM unprotected left main.
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UNPROTECTED LEFT MAIN ASSESSMENTrevascularization and those with an MLA
P7.5 mm2 deferred for revascularization [45].
Mintz [46] postulated that MLA <6 mm2 makes
the stenosis significant. He proposed another
parameter crucial for ULM lesion significance:
lumen stenosis higher than 50%. This approach,
which is the most commonly used, may verify the
ULM size and thus provide proper stenosis assess-
ment, especially of a diffusely diseased vessel.
In a multicenter prospective study, de la Torre
Hernandez et al. used a MLA of 6 mm2 as a cutoff
value for deferring revascularization of the ULM
[47]. In a two-year follow up period, no significant
differences were observed between the deferred
group and the revascularized group in cardiac
death-free survival (97.7% vs. 94.5%; p = 0.5), and
event-free survival (87.3% vs. 80.6%; p = 0.3) [47].
Although IVUS is not recommended for routine
lesion assessment, current American guidelines
assign to it a Class IIa, Level of Evidence: B indica-
tion in undetermined ostial ULM disease [48].
IVUS is also employed to evaluate results after
ULM PCI especially in case of distal ULM treat-
ment. Indeed, IVUS in ULM intervention is able
to evaluate stent under-expansion, incomplete
lesion coverage, small stent area, large residual
plaque, and stent malapposition, which have been
found to predict stent thrombosis after DES place-
ment [49–50]. In the MAIN-COMPARE registry,
Park et al. showed that elective stenting with IVUS
guidance, especially in the placement of drug-
eluting stents, may reduce the long-term mortality
rate for unprotected left main coronary artery
stenosis when compared with conventional angi-
ography guidance. Non-randomized data reported
that overall survival or event-free survival
is improved when IVUS is used during ULM
PCI [51].
In a cohort of 1670 patients, de la Torre Hernan-
dez et al. showed association of IVUS guidance
during PCI with better outcomes in patients with
ULM disease undergoing revascularization with
DES [52]. Indeed, IVUS-guided procedure was
identified as a protective predictor for major
adverse events in the overall population (hazard
ratio = 0.70) and the distal ULM subgroup (hazard
ratio = 0.54) [52].
In case of distal ULM treatment, IVUS may also
play a role in the selection of the most appropriate
stenting technique. Indeed, systemic use of a two-
stent strategy, compared with a single-stent strat-
egy, may increase the risk of stent thrombosis as
well as repeat revascularization in bifurcation
ULM lesions [53]. A better insight into plaque con-
figuration with IVUS can diminish the unnecessaryuse of two-stent procedures by distinguishing true
stenosis versus pseudo-stenosis caused by various
artifacts, including the device, coronary spasm, or
calcification at the side branch [54].Ultrasound-based virtual histology
Greyscale IVUS is the gold standard modality
for in vivo imaging of the vessel wall of the coro-
nary arteries [55]. However, the greyscale repre-
sentation of the coronary artery wall and plaque
morphology associated with the limited resolution
of current IVUS catheters makes it difficult to
qualitatively identify plaque morphology similar
to that of histopathology, which is the gold stan-
dard in characterizing and quantifying coronary
plaque tissue components [56]. Innovative IVUS-
based methods, such as virtual histology IVUS,
based on interpretation of the raw radiofrequency
analysis has been introduced [57–59]. Although
this technique has been validated in vitro and
ex vivo in human and animal models [57–60],
results regarding its ability to qualitatively and
quantitatively identify plaque components cor-
rectly remains controversial [61–63]. The main
criticism stems from the fact that due to biological
differences between animals and humans, the tis-
sue types contained in animal atherosclerotic
lesions may not be similar to the lesions seen in
human disease. Other studies have compared vir-
tual histology in human coronary arteries with
other intra-coronary imaging techniques devel-
oped for the detection of necrotic core, finding a
poor correlation [63,64]. Brugaletta et al. [63]
showed that sensitivity and specificity of virtual
histology for detection of necrotic core were both
a modest 41.1% and 51%, respectively. Valgimigli
et al. [65] employed IVUS-based virtual histology
to study the plaque composition in left main
stems. The authors found that the plaque necrotic
content was minimal in the ULM, particularly in
the most proximal tract, whereas it peaked in the
first 6-mm segments after the ostium of the two
major left coronaries. The length of ULM was
shown to affect the distribution of necrotic core
along the vessel. Indeed, in patients with long
ULM, necrotic core content peaked immediately
in the first coronary segment after the left main
stem. Conversely, the necrotic core content
peaked in the second 6-mm segment in patients
with short left main stem and resulted in an
increase in the two most distally analyzed seg-
ments compared to the long left main stem group
[65]. Such findings confirmed the pathological
studies results which have suggested that the
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plaques at high risk for rupture, are infrequent in
the left main stem [66]. However, the benefits of
the virtual histology technique in ULM assess-
ment remains undetermined.
Optical coherence tomography
Optical coherence tomography (OCT) is an opti-
cal analog of intravascular ultrasound (IVUS) that
can be used to examine the coronary arteries and
has 10-fold higher resolution than IVUS. Indeed,
OCT provides cross-sectional images with power-
ful resolution (10–20 lm) [67]. However, the first
generation time-domain OCT systems had a rela-
tively narrow field of view and required proximal
vessel occlusion for image acquisition, precluding
its application in ULM. Several studies have
reported the safety and feasibility of the new fre-
quency-domain OCT (FD-OCT) imaging in the
clinical setting of non-ULM lesions [68–73]. Fujino
et al. [74] employed FD-OCT to assess, guide, and
monitor outcomes of PCI in ULM coronary dis-
ease, and showed a similar high safety and feasi-
bility profile compared with IVUS both pre- and
post-PCI. However, FD-OCT was associated with
the use of additional iodine contrast and required
more imaging pullbacks than IVUS [74]. More-
over, ostial ULM lesions are extremely challeng-
ing to assess with OCT.
Despite having established the clinical useful-
ness of IVUS, the literature is still lacking for
OCT although this technique is currently limited
by its penetration depth (1–3 mm) and its need
for a blood cleared environment to obtain image
production, it nonetheless appears to be a power-
ful imaging tool for the characterization of stent
deployment in PCI. In fact, OCT enables the iden-
tification of a region of stent-strut malapposition
that is unapparent angiographically. Following
higher pressure and larger balloon inflation,
OCT imaging showed optimal stent-strut apposi-
tion in great detail and without complications in
its performance. Several case reports have been
published about the management of ULM lesions
using OCT [75,76]. Further multicentric random-
ized studies are necessary to investigate the real
impact of OCT in ULM PCI.
Fractional flow reserve
The characteristics of fractional flow reserve
(FFR) have been extensively described and
validated over recent years [77,78]. FFR is a lesion
specific index with unsurpassed sensitivity, speci-
ficity, and spatial resolution for the detection of
inducible ischemia [79]. Its prognostic value forsingle and multi-vessel disease as well as left main
disease has been demonstrated [80–83]. FFR was
first validated using a cutoff value of 0.75. With
further experience in the technique, investigators
appreciated that by extending the cutoff value to
0.80, the sensitivity of FFR could be improved
without greatly compromising the specificity. For
this reason, a cutoff value of 60.80 was used in
FAME 1 and FAME 2, and shown to be clinically
valid [84]. However, FFR <0.75 is the effective cut-
off for guiding revascularization decisions and
evaluating intermediate ULM lesions [85].
Several caveats should be taken into account
when using FFR for left main assessment. The
method is indeed critically dependent not only
on the anatomical characteristics of the lesion
itself, but also on the vascular bed supplied by
the left main trunk. The presence of a tight steno-
sis in one of the branches of the left main can also
alter the pressure gradient across the left main,
causing an overestimation of FFR if measured on
the other branch [86]. Furthermore, if the right
coronary artery is severely diseased or occluded
and contralateral collateral flow is present, the
vascular bed supplied by the ULM is increased.
In this case, FFR may be reduced with a stenosis
that would not be significant in the absence of
the occluded vessel [87].
Jasti et al. [88] studied 55 ambiguous left main
stenoses with IVUS as well as FFR and found that
an IVUS MLA of 5.9 mm2 or a minimal luminal
diameter of 2.8 mm were predictive of FFR <0.75
with 93% sensitivity and 95% specificity [88]. Kang
et al. [89] showed that an IVUS MLA of 4.8 and
4.1 mm2 were predictive of an FFR value <0.8
and <0.75, respectively. All patients with an MLA
>6 mm2 had a negative FFR; 82% of patients with
an MLA <4.8 mm2 had an FFR <0.8. A high inci-
dence of plaque rupture was found by IVUS
(33%), and ruptured plaques had a lower FFR
value than non-ruptured ones, even if the average
MLA was not significantly different [89,90].Conclusion
The optimal therapeutic strategy for patients
with ULM disease is still controversial. An optimal
result passes through rational risk stratification
and better assessment of ULM stenosis. IVUS
and FFR are two complementary modalities in
ULM lesion assessment: FFR remains a simple
and reliable tool to assess the functional signifi-
cance of intermediate lesions in the presence of
isolated ULM disease. However, IVUS is strongly
preferred when other lesions are present. Both
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OCT also represents a valid alternative to assess
stent apposition after ULM PCI.R
EReferences
[1] Taggart DP, Kaul S, Boden WE, Ferguson Jr TB, Guyton
RA, Mack MJ, et al.. Revascularization for unprotected left
main stem coronary artery stenosis stenting or surgery. J
Am Coll Cardiol 2008;51(9):885–92.
[2] Caracciolo EA, Davis KB, Sopko G, Kaiser GC, Corley SD,
Schaff H, et al.. Comparison of surgical and medical group
survival in patients with left main coronary artery disease.
Long-term CASS experience. Circulation 1995;91(9):
2325–34.
[3] Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy
JW, et al.. Effect of coronary artery bypass graft surgery on
survival: overview of 10-year results from randomised trials
by the coronary artery bypass graft surgery trialists
collaboration. Lancet 1994;344(8922): 563–70.
[4] Tamburino C, Angiolillo DJ, Capranzano P, Di Salvo M,
Ussia G, La Manna A, et al.. Long-term clinical outcomes
after drug-eluting stent implantation in unprotected left
main coronary artery disease. Catheter Cardiovasc Interv
2009;73(3):291–8.
[5] Tamburino C, Angiolillo DJ, Capranzano P, Dimopoulos K,
La Manna A, Barabagallo R, et al.. Complete versus
incomplete revascularization in patients with multivessel
disease undergoing percutaneous coronary intervention
with drug-eluting stents. Catheter Cardiovasc Interv
2008;72(4):448–56.
[6] Prati F, Petronio S, Van Boven AJ, Tendera M, De Luca L,
de Belder MA, et al.. Evaluation of infarct-related coronary
artery patency and microcirculatory function after
facilitated percutaneous primary coronary angioplasty:
the FINESSE-ANGIO (facilitated intervention with
enhanced reperfusion speed to stop events-angiographic)
study. JACC Cardiovasc Interv 2010;3(12):1284–91.
[7] Galassi AR, Tomasello SD, Costanzo L, Campisano MB,
Barrano G, Tamburino C. Long-term clinical and
angiographic results of sirolimus-eluting stent in complex
coronary chronic total occlusion revascularization: the
SECTOR registry. J Interv Cardiol 2011;24(5):426–36.
[8] Galassi AR, Tomasello SD, Crea F, Costanzo L, Campisano
MB, Marzá F, et al.. Transient impairment of vasomotion
function after successful chronic totalocclusion
recanalization. J Am Coll Cardiol 2012;59(8):711–8.
[9] Serruys PW, Onuma Y, Garg S, Vranckx P, De Bruyne B,
Morice MC, et al.. 5-year clinical outcomes of the ARTS II
(arterial revascularization therapies study II) of the
sirolimus-eluting stent in the treatment of patients with
multivessel de novo coronary artery lesions. J Am Coll
Cardiol 2010;55(11):1093–101.
[10] Galassi AR, Tomasello SD, Capodanno D, Barrano G, Ussia
GP, Tamburino C. Mini-crush versus T-provisional
techniques in bifurcation lesions: clinical and angiographic
long-term outcome after implantation of drug-eluting
stents. JACC Cardiovasc Interv 2009;2(3): 185–94.
[11] Kappetein AP, Dawkins KD, Mohr FW, Morice MC, Mack
MJ, Russell ME, et al.. Current percutaneous coronary
intervention and coronary artery bypass grafting practices
for three-vessel and left main coronary artery disease.
Insights from the SYNTAX run-in phase. Eur J
Cardiothorac Surg 2006;29(4):486–91.
[12] Kandzari DE, Colombo A, Park SJ, Tommaso CL, Ellis SG,
Guzman LA, et al.. Revascularization for unprotected left
main disease: evolution of the evidence basis to redefine
treatment standards. J Am Coll Cardiol 2009;54(17):
1576–88.
[13] Serruys PW, Morice MC, Kappetein AP, Colombo A,
Holmes DR, Mack MJ, et al.. Percutaneous coronaryintervention versus coronary-artery bypass grafting for
severe coronary artery disease. N Engl J Med 2009;360(10):
961–72.
[14] Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet
T, et al.. Guidelines on myocardial revascularization. Task
force on myocardial revascularization of the european
society of cardiology (ESC) and the European Association
for Cardio-Thoracic Surgery (EACTS). Eur Heart J
2010;31(20):2501–55.
[15] McDaniel MC, Eshtehardi P, Sawaya FJ, Douglas Jr JS,
Samady H. Contemporary clinical applications of coronary
intravascular ultrasound. JACC Cardiovasc Interv
2011;4(11):1155–67.
[16] Cohen MV, Gorlin R. Main left coronary artery disease.
Clinical experience from 1964–1974. Circulation 1975;52(2):
275–85.
[17] Lee MS, Kapoor N, Jamal F, Czer L, Aragon J, Forrester J,
et al.. Comparison of coronary artery bypass surgery with
percutaneous coronary intervention with drug-eluting
stents for unprotected left main coronary artery disease.
J Am Coll Cardiol 2006;47(4):864–70.
[18] Ellis SG, Hill CM, Lytle BW. Spectrum of surgical risk for
left main coronary stenoses: benchmark for potentially
competing percutaneous therapies. Am Heart J 1998;135(2
Pt 1):335–8.
[19] Nashef SA, Sharples LD, Roques F, Lockowandt U.
EuroSCORE II and the art and science of risk modelling.
Eur J Cardiothorac Surg 2013;43(4):695–6.
[20] Morice MC, Serruys PW, Kappetein AP, Feldman TE,
Ståhle E, Colombo A, et al.. Outcomes in patients with de
novo left main disease treated with either percutaneous
coronary intervention using paclitaxel-eluting stents or
coronary artery bypass graft treatment in the synergy
between coronary intervention with TAXUS and cardiac
surgery (SYNTAX) trial. Circulation 2010;121(24):2645–53.
[21] Kim YH, Park DW, Kim WJ, Lee JY, Yun SC, Kang SJ, et al..
Validation of SYNTAX (Synergy between PCI with Taxus
and Cardiac Surgery) score for prediction of outcomes
after unprotected left main coronary revascularization.
JACC Cardiovasc Interv 2010;3(6):612–23.
[22] Kim YH, Ahn JM, Park DW, Lee BK, Lee CW, Hong MK,
et al.. EuroSCORE as a predictor of death and myocardial
infarction after unprotected left main coronary stenting.
Am J Cardiol 2006;98(12):1567–70.
[23] Romagnoli E, Burzotta F, Trani C, Siviglia M, Biondi-Zoccai
GG, Niccoli G, et al.. EuroSCORE as predictor of in-hospital
mortality after percutaneous coronary intervention. Heart
2009;95(1):43–8.
[24] Rodés-Cabau J, Deblois J, Bertrand OF, Mohammadi S,
Courtis J, Larose E, et al.. Nonrandomized comparison of
coronary artery bypass surgery and percutaneous
coronary intervention for the treatment of unprotected
left main coronary artery disease in octogenarians.
Circulation 2008;118(23):2374–81.
[25] Shahian DM, O’Brien SM, Filardo G, Ferraris VA, Haan
CK, Rich JB, et al.. The society of thoracic surgeons 2008
cardiac surgery risk models. Part 1. Coronary artery
bypass grafting surgery. Ann Thorac Surg 2009;88(1
Suppl):S2–S22.
[26] Krzych ŁJ, Bochenek-Klimczyk K, Wasiak M, Bialek K,
Bolkowski M, Gierek D, et al.. Left main disease
management strategy: indications and revascularization
methods in particular groups of subjects. Cardiol J
2012;19(4):347–54.
[27] Ranucci M, Castelvecchio S, Menicanti L, Frigiola A,
Pelissero G. Risk of assessing mortality risk in elective
cardiac operations: age, creatinine, ejection fraction, and
the law of parsimony. Circulation 2009;119(24):3053–61.
[28] Singh M, Gersh BJ, Li S, Rumsfeld JS, Spertus JA, O’Brien
SM, et al.. Mayo clinic risk score for percutaneous
coronary intervention predicts in-hospital mortality in
patients undergoing coronary artery bypass graft surgery.
Circulation 2008;117(3):356–62.
R
EV
IEW
 A
RTIC
LE
116 BOUKHRIS ET AL
UNPROTECTED LEFT MAIN ASSESSMENT
J Saudi Heart Assoc
2015;27:109–117[29] Serruys PW, Onuma Y, Garg S, Sarno G, van den Brand
M, Kappetein AP, et al.. Assessment of the SYNTAX score
in the Syntax study. EuroIntervention 2009;5(1):50–6.
[30] Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo
A, Dawkins K, et al.. The SYNTAX Score: an angiographic
tool grading the complexity of coronary artery disease.
EuroIntervention 2005;1(2):219–27.
[31] Farooq V, Girasis C, Magro M, Onuma Y, Morel MA, Heo
JH, et al.. The coronary artery bypass graft SYNTAX Score:
final five-year outcomes from the SYNTAX-LE MANS left
main angiographic substudy. EuroIntervention 2013;9(8):
1009–10.
[32] Genereux P, Xu B, Yang Y, Xu L, Qiao S, Wu Y, et al.. TCT-
418 confirmation of the prognostic capability of the syntax
score-II among 1528 patients who underwent left main
PCI. J Am Coll Cardiol 2013;62(18_S1):B130.
[33] Brueren BR, ten Berg JM, Suttorp MJ, Bal ET, Ernst JM,
Mast EG, et al.. How good are experienced cardiologists at
predicting the hemodynamic severity of coronary stenoses
when taking fractional flow reserve as the gold standard.
Int J Cardiovasc Imaging 2002;18(2):73–6.
[34] Bartúnek J, Sys SU, Heyndrickx GR, Pijls NH, De Bruyne
B. Quantitative coronary angiography in predicting
functional significance of stenoses in an unselected
patient cohort. J Am Coll Cardiol 1995;26(2):328–34.
[35] Hamilos M, Muller O, Cuisset T, Ntalianis A, Chlouverakis
G, Sarno G, et al.. Long-term clinical outcome after
fractional flow reserve-guided treatment in patients with
angiographically equivocal left main coronary artery
stenosis. Circulation 2009;120(15):1505–12.
[36] Botman CJ, Schonberger J, Koolen S, Penn O, Botman H,
Dib N, et al.. Does stenosis severity of native vessels
influence bypass graft patency? A prospective fractional
flow reserve-guided study. Ann Thorac Surg 2007;83(6):
2093–7.
[37] Lindstaedt M, Spiecker M, Perings C, Lawo T, Yazar A,
Holland-Letz T, et al.. How good are experienced
interventional cardiologists at predicting the functional
significance of intermediate or equivocal left main
coronary artery stenoses? Int J Cardiol 2007;120(2):
254–61.
[38] Tamburino C, Capranzano P, Capodanno D, Tagliareni F,
Biondi-Zoccai G, Sanfilippo A, et al.. Plaque distribution
patterns in distal left main coronary artery to predict
outcomes after stent implantation. JACC Cardiovasc
Interv 2010;3(6):624–31.
[39] Hermiller JB, Buller CE, Tenaglia AN, Kisslo KB, Phillips
HR, Bashore TM, et al.. Unrecognized left main coronary
artery disease in patients undergoing interventional
procedures. Am J Cardiol 1993;71(2):173–6.
[40] Yamagishi M, Hongo Y, Goto Y, Umeno T, Tsutsui H,
Asanuma T, et al.. Intravascular ultrasound evidence of
angiographically undetected left main coronary artery
disease and associated trauma during interventional
procedures. Heart Vessels 1996;11(5):262–8.
[41] Gerber TC, Erbel R, Görge G, Ge J, Rupprecht HJ, Meyer J.
Extent of atherosclerosis and remodeling of the left main
coronary artery determined by intravascular ultrasound.
Am J Cardiol 1994;73(9):666–71.
[42] Nissen SE, Yock P. Intravascular ultrasound: novel
pathophysiological insights and current clinical
applications. Circulation 2001;103(4):604–16.
[43] Takahashi T, Honda Y, Russo RJ, Fitzgerald PJ.
Intravascular ultrasound and quantitative coronary
angiography. Catheter Cardiovasc Interv 2002;55(1):
118–28.
[44] Abizaid AS, Mintz GS, Abizaid A, Mehran R, Lansky AJ,
Pichard AD, et al.. One-year follow-up after intravascular
ultrasound assessment of moderate left main coronary
artery disease in patients with ambiguous angiograms. J
Am Coll Cardiol 1999;34(3):707–15.
[45] Fassa AA, Wagatsuma K, Higano ST, Mathew V, Barsness
GW, Lennon RJ, et al.. Intravascular ultrasound-guided
treatment for angiographically indeterminate left maincoronary artery disease: a long-term follow-up study. J Am
Coll Cardiol 2005;45(2):204–11.
[46] Mintz GS, Weissman NJ. Intravascular ultrasound in the
drug-eluting stent era. J Am Coll Cardiol 2006;48(3):421–9.
[47] de la Torre Hernandez JM, Hernández Hernandez F,
Alfonso F, Rumoroso JR, Lopez-Palop R, Sadaba M, et al..
Prospective application of pre-defined intravascular
ultrasound criteria for assessment of intermediate left
main coronary artery lesions results from the multicenter
LITRO study. J Am Coll Cardiol 2011;58(4):351–8.
[48] Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA,
Cercek B, et al.. 2011 ACCF/AHA/SCAI guideline for
percutaneous coronary intervention: a report of the
American College of Cardiology Foundation/American
Heart Association Task Force on Practice Guidelines and
the Society for Cardiovascular Angiography and
Interventions. Circulation 2011;124(23):e574–651.
[49] Furukawa E, Hibi K, Kosuge M, Nakatogawa T, Toda N,
Takamura T, et al.. Intravascular ultrasound predictors of
side branch occlusion in bifurcation lesions after
percutaneous coronary intervention. Circ J 2005;69(3):
325–30.
[50] Chieffo A, Park SJ, Meliga E, Sheiban I, Lee MS, Latib A,
et al.. Late and very late stent thrombosis following drug-
eluting stent implantation in unprotected left main
coronary artery: a multicentre registry. Eur Heart J
2008;29(17):2108–15.
[51] Park SJ, Kim YH, Park DW, Lee SW, Kim WJ, Suh J, et al..
Impact of intravascular ultrasound guidance on long-term
mortality in stenting for unprotected left main coronary
artery stenosis. Circ Cardiovasc Interv 2009;2(3):167–77.
[52] de la Torre Hernandez JM, Baz Alonso JA, Gómez Hospital
JA, Alfonso Manterola F, Garcia Camarero T, Gimeno de
Carlos F, et al.. Clinical impact of intravascular ultrasound
guidance in drug-eluting stent implantation for
unprotected left main coronary disease: pooled analysis
at the patient-level of 4 registries. JACC Cardiovasc Interv
2014;7(3):244–54.
[53] Alfonso F, Suárez A, Pérez-Vizcayno MJ, Moreno R,
Escaned J, Bañuelos C, et al.. Intravascular ultrasound
findings during episodes of drug-eluting stent thrombosis.
J Am Coll Cardiol 2007;50(21):2095–7.
[54] Fitzgerald PJ, Oshima A, Hayase M, Metz JA, Bailey SR,
Baim DS, et al.. Final results of the can routine ultrasound
influence stent expansion (CRUISE) study. Circulation
2000;102(5):523–30.
[55] Garcia-Garcia HM, Costa MA, Serruys PW. Imaging of
coronary atherosclerosis: intravascular ultrasound. Eur
Heart J 2010;31(20):2456–69.
[56] Garcia-Garcia HM, Gogas BD, Serruys PW, Bruining N.
IVUS-based imaging modalities for tissue
characterization: similarities and differences. Int J
Cardiovasc Imaging 2011;27(2):215–24.
[57] Nair A, Kuban BD, Tuzcu EM, Schoenhagen P, Nissen SE,
Vince DG. Coronary plaque classification with
intravascular ultrasound radiofrequency data analysis.
Circulation 2002;106(17):2200–6.
[58] Nair A, Margolis MP, Kuban BD, Vince DG. Automated
coronary plaque characterisation with intravascular
ultrasound backscatter: ex vivo validation.
EuroIntervention 2007;3(1):113–20.
[59] García-García HM, Mintz GS, Lerman A, Vince DG,
Margolis MP, van Es GA, et al.. Tissue characterisation
using intravascular radiofrequency data analysis:
recommendations for acquisition, analysis, interpretation
and reporting. EuroIntervention 2009;5(2):177–89.
[60] Nasu K, Tsuchikane E, Katoh O, Vince DG, Virmani R,
Surmely JF, et al.. Accuracy of in vivo coronary plaque
morphology assessment: a validation study of in vivo
virtual histology compared with in vitro histopathology. J
Am Coll Cardiol 2006;47(12):2405–12.
[61] Thim T, Hagensen MK, Wallace-Bradley D, Granada JF,
Kaluza GL, Drouet L, et al.. Unreliable assessment of
necrotic core by virtual histology intravascular ultrasound
R
EV
IE
W
 A
RT
IC
LE
J Saudi Heart Assoc
2015;27:109–117
BOUKHRIS ET AL 117
UNPROTECTED LEFT MAIN ASSESSMENTin porcine coronary artery disease. Circ Cardiovasc
Imaging 2010;3(4):384–91.
[62] Granada JF, Wallace-Bradley D, Win HK, Alviar CL, Builes
A, Lev EI, et al.. In vivo plaque characterization using
intravascular ultrasound-virtual histology in a porcine
model of complex coronary lesions. Arterioscler Thromb
Vasc Biol 2007;27(2):387–93.
[63] Brugaletta S, Garcia-Garcia HM, Serruys PW, de Boer S,
Ligthart J, Gomez-Lara J, et al.. NIRS and IVUS for
characterization of atherosclerosis in patients undergoing
coronary angiography. JACC Cardiovasc Imaging
2011;4(6):647–55.
[64] Pu J, Mintz GS, Brilakis ES, Banerjee S, Abdel-Karim AR,
Maini B, et al.. In vivo characterization of coronary
plaques: novel findings from comparing greyscale and
virtual histology intravascular ultrasound and near-
infrared spectroscopy. Eur Heart J 2012;33(3):372–83.
[65] Valgimigli M, Rodriguez-Granillo GA, Garcia-Garcia HM,
Vaina S, De Jaegere P, De Feyter P, et al.. Plaque
composition in the left main stem mimics the distal but
not the proximal tract of the left coronary artery: influence
of clinical presentation, length of the main trunk, lipid
profile, and systemic levels of C-reactive protein. J Am
Coll Cardiol 2007;49(1):23–31.
[66] Kolodgie FD, Burke AP, Farb A, Gold HK, Yuan J, Narula J,
et al.. The thin-cap fibroatheroma: a type of vulnerable
plaque: the major precursor lesion to acute coronary
syndromes. Curr Opin Cardiol 2001;16(5):285–92.
[67] Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM,
Stankovic G, et al.. Incidence, predictors, and outcome of
thrombosis after successful implantation of drug-eluting
stents. JAMA 2005;293(17):2126–30.
[68] Stefano GT, Bezerra HG, Mehanna E, Yamamoto H, Fujino
Y, Wang W, et al.. Unrestricted utilization of frequency
domain optical coherence tomography in coronary
interventions. Int J Cardiovasc Imaging 2013;29(4):741–52.
[69] Yoon JH, Di Vito L, Moses JW, Fearon WF, Yeung AC,
Zhang S, et al.. Feasibility and safety of the second-
generation, frequency domain optical coherence
tomography (FD-OCT): a multicenter study. J Invasive
Cardiol 2012;24(5):206–9.
[70] Prati F, Di Vito L, Biondi-Zoccai G, Occhipinti M, La
Manna A, Tamburino C, et al.. Angiography alone versus
angiography plus optical coherence tomography to guide
decision-making during percutaneous coronary
intervention: the Centro per la Lotta contro l’Infarto-
Optimisation of Percutaneous Coronary Intervention
(CLI-OPCI) study. EuroIntervention 2012;8(7):823–9.
[71] Imola F, Mallus MT, Ramazzotti V, Manzoli A, Pappalardo
A, Di Giorgio A, et al.. Safety and feasibility of frequency
domain optical coherence tomography to guide decision
making in percutaneous coronary intervention.
EuroIntervention 2010;6(5):575–81.
[72] Takarada S, Imanishi T, Liu Y, Ikejima H, Tsujioka H,
Kuroi A, et al.. Advantage of next-generation frequency-
domain optical coherence tomography compared with
conventional time-domain system in the assessment of
coronary lesion. Catheter Cardiovasc Interv 2010;75(2):
202–6.
[73] Niccoli G, Ferrante G, Galassi AR, Montone RA, Crea F.
Optical coherence tomography follow-up of the subintimal
tracking and re-entry technique for chronic total occlusion.
EuroIntervention 2010;6(5):662–3.
[74] Fujino Y, Bezerra HG, Attizzani GF, Wang W, Yamamoto
H, Chamié D, et al.. Frequency-domain optical coherence
tomography assessment of unprotected left main coronary
artery disease-a comparison with intravascular
ultrasound. Catheter Cardiovasc Interv 2013;82(3):E173–83.
[75] Alcock R, Yong AS, Yannikas J, Lowe HC. Optical
coherence tomography-guided left main stem stenting: a
new approach? Tex Heart Inst J 2012;39(4):596–7.[76] Moharram MA, Yeoh T, Lowe HC. Swings and
roundabouts: intravascular optical coherence
tomography (OCT) in the evaluation of the left main
stem coronary artery. Int J Cardiol 2011;148(2):243–4.
[77] De Bruyne B, Baudhuin T, Melin JA, Pijls NH, Sys SU, Bol
A, et al.. Coronary flow reserve calculated from pressure
measurements in humans. Validation with positron
emission tomography. Circulation 1994;89(3):1013–22.
[78] De Bruyne B, Bartunek J, Sys SU, Pijls NH, Heyndrickx
GR, Wijns W. Simultaneous coronary pressure and flow
velocity measurements in humans. Feasibility,
reproducibility, and hemodynamic dependence of
coronary flow velocity reserve, hyperemic flow versus
pressure slope index, and fractional flow reserve.
Circulation 1996;94(8):1842–9.
[79] Pijls NH, De Bruyne B, Peels K, Van Der Voort PH,
Bonnier HJ, Bartunek J, et al.. Measurement of fractional
flow reserve to assess the functional severity of coronary-
artery stenoses. N Engl J Med 1996;334(26):1703–8.
[80] Bech GJ, De Bruyne B, Pijls NH, de Muinck ED, Hoorntje
JC, Escaned J, et al.. Fractional flow reserve to determine
the appropriateness of angioplasty in moderate coronary
stenosis: a randomized trial. Circulation 2001;103(24):
2928–34.
[81] Berger A, Botman KJ, MacCarthy PA, Wijns W, Bartunek J,
Heyndrickx GR, et al.. Long-term clinical outcome after
fractional flow reserve-guided percutaneous coronary
intervention in patients with multivessel disease. J Am
Coll Cardiol 2005;46(3):438–42.
[82] Pijls NH, Klauss V, Siebert U, Powers E, Takazawa K,
Fearon WF, et al.. Coronary pressure measurement after
stenting predicts adverse events at follow-up: a
multicenter registry. Circulation 2002;105(25):2950–4.
[83] Legalery P, Schiele F, Seronde MF, Meneveau N, Wei H,
Didier K, et al.. One-year outcome of patients submitted to
routine fractional flow reserve assessment to determine
the need for angioplasty. Eur Heart J 2005;26(24):2623–9.
[84] Melikian N, De Bondt P, Tonino P, De Winter O, Wyffels
E, Bartunek J, et al.. Fractional flow research and
myocardial perfusion imaging in patients with
angiographic multivessel coronary artery disease. JACC
Cardiovasc Interv 2010;3(3):307–14.
[85] Lotfi A, Jeremias A, Fearon WF, Feldman MD, Mehran R,
Messenger JC, et al.. Expert consensus statement on the
use of fractional flow reserve, intravascular ultrasound,
and optical coherence tomography: a consensus statement
of the society of cardiovascular angiography and
interventions. Catheter Cardiovasc Interv 2014;83(4):
509–18.
[86] Daniels DV, van’t Veer M, Pijls NH, van der Horst A, Yong
AS, De Bruyne B, et al.. The impact of downstream
coronary stenoses on fractional flow reserve assessment
of intermediate left main disease. JACC Cardiovasc Interv
2012;5(10):1021–5.
[87] Iqbal MB, Shah N, Khan M, Wallis W. Reduction in
myocardial perfusion territory and its effect on the
physiological severity of a coronary stenosis. Circ
Cardiovasc Interv 2010;3(1):89–90.
[88] Jasti V, Ivan E, Yalamanchili V, Wongpraparut N, Leesar
MA. Correlations between fractional flow reserve and
intravascular ultrasound in patients with an ambiguous
left main coronary artery stenosis. Circulation
2004;110(18):2831–6.
[89] Kang SJ, Lee JY, Ahn JM, Song HG, Kim WJ, Park DW,
et al.. Intravascular ultrasound-derived predictors for
fractional flow reserve in intermediate left main disease.
JACC Cardiovasc Interv 2011;4(11):1168–74.
[90] Park SJ, Kang SJ, Ahn JM, Shim EB, Kim YT, Yun SC, et al..
Visual-functional mismatch between coronary
angiography and fractional flow reserve. JACC Cardiovasc
Interv 2012;5(10):1029–36.
